{"componentChunkName":"component---src-templates-blog-post-js","path":"/pharmacovigilance/","result":{"data":{"site":{"siteMetadata":{"title":"Medwork","author":"Ioannis Tsiakkas"}},"markdownRemark":{"id":"9118d9d5-e35d-5344-a65e-eab42d6cb2f7","excerpt":"","html":"<p>\n    <blockquote>\n        Compliance with pharmacovigilance requirements is becoming an increasing challenge for pharmaceutical companies worldwide. In this very demanding environment,\n        Medwork offers a reliable solution for every need related to drug safety.\n        We have an extensive Pharmacovigilance Department composed of a team of 21 pharmacovigilance professionals and four medical advisors.\n        Our clients range from small local companies to large international corporations. Currently [Dec 2021 data], we have over 117\n        active contracts with more than 77 clients relating to pharmacovigilance activities.\n        Our services may be fully customized to cover all of a Marketing Authorization Holder’s responsibilities related to drug safety.\n    </blockquote>\n    <h3>Full pharmacovigilance Support</h3>\n          <p>\n            Medwork's dedicated professionals will ensure full compliance of\n            Marketing Authorization Holders with their regulatory obligations.\n            We provide full pharmacovigilance coverage as well as tailored\n            services that cover specific needs. Our services include:\n            <br />\n            <br />\n            <b>Full Post-Marketing Pharmacovigilance Support:</b>\n            <br />\n            <ul>\n              <li>Establishment of a pharmacovigilance System</li>\n              <li>Undertaking EU QPPV/deputy EU QPPV responsibility</li>\n              <li>Local & global literature review</li>\n              <li>Compilation and maintenance of the PSMF</li>\n              <li>Safety information processing</li>\n              <li>Writing and/or reviewing periodic reports</li>\n              <li>Writing RMPs</li>\n              <li>Interaction with Eudravigilance database including XEVMPD</li>\n              <li>DHPC management</li>\n              <li>Pharmacovigilance personnel back-up</li>\n              <li>\n                Training of pharmacovigilance and non-pharmacovigilance\n                personnel\n              </li>\n              <li>Consulting</li>\n            </ul>\n            <b>Clinical Trials Pharmacovigilance Support:</b>\n            <ul>\n              <li>\n                Provision of Responsible Person for pharmacovigilance (RP) for\n                clinical trials\n              </li>\n              <li>Eudravigilance registration</li>\n              <li>Assessment and medical review of serious adverse events</li>\n              <li>\n                SUSAR reporting to Eudravigilance and Competent Authorities\n              </li>\n              <li>Ongoing risk/benefit assessment of the IMP</li>\n              <li>Compilation and update of the DSUR</li>\n            </ul>\n          </p>\n    <h3>Local literature review for Greece & Cyprus</h3>\n          <p>\n            Medwork operates a comprehensive medical literature monitoring\n            service for Greece and Cyprus.We identify and report to contracted\n            Marketing Authorization Holders safety information that qualifies\n            for ICSR reporting, ongoing product risk- benefit evaluation and\n            PSUR preparation.\n            <ul>\n              <li>\n                GREECE: The local Medical Literature Monitoring(service) for\n                Greece includes the review of over 94 Greek medical journals, as\n                well as the published proceedings of local medical\n                conferences.The service is currently provided to a total of 72\n                companies[Dec 2021 data], ranging from small Greek and European\n                companies to local affiliates of international pharmaceutical\n                companies(including eight of the top 10 global pharmaceutical\n                companies).\n              </li>\n              <li>\n                CYPRUS: The local Medical Literature Monitoring(service)\n                includes the review of 2 Cypriot medical journals as well as\n                published proceedings of local medical conferences.There are\n                currently active contracts with a total of 30 pharmaceutical\n                companies [Dec 2021 data], mainly European and local affiliates\n                of international pharmaceutical companies.\n              </li>\n            </ul>\n          </p>\n    <h3>Local QP for Greece & Cyprus</h3>\n          <p>\n            Greece and Cyprus are among the EU countries that{\" \"}\n            <b>\n              require the appointment of a local Qualified Person for\n              pharmacovigilance\n            </b>\n            , as per the article 104 of Directive 2010/84/EU: “national\n            competent authorities may request the nomination of a contact person\n            for pharmacovigilance issues at national level reporting to the\n            qualified person responsible for pharmacovigilance activities.”\n            Medwork has dedicated, properly qualified, local staff in both\n            countries, who can assume the role and responsibilities of the local\n            QP for pharmacovigilance as well as her/his deputy. Further local\n            pharmacovigilance services include:\n            <ul>\n              <li>\n                Handling of safety information as per relevant local regulations\n              </li>\n              <li>Medical information handling</li>\n              <li>Handling of technical complaints about products</li>\n              <li>\n                Regulatory intelligence-monitoring of local legislation\n                governing pharmacovigilance, medical information and PTC\n                handling and informing contracted MAHs\n              </li>\n            </ul>\n          </p>\n    <h3>Consultancy & Training</h3>\n          <p>\n            <b>Consultancy services</b>\n            <br />\n            Medwork <b>consults</b> Marketing Authorization Holders on all\n            aspects of pharmacovigilance obligations, such as:\n            <br />\n            Establishment of a suitable and adequate pharmacovigilance system\n            Management of safety agreements Handling of risk management plans\n            Setting up of a suitable risk-benefit evaluation process\n            Establishment of the appropriate quality structure to support the\n            pharmacovigilance system Special local pharmacovigilance obligations\n            in Greece & Cyprus\n            <br />\n            <br />\n            <b>Training services</b>\n            <br />\n            Medwork offers complete <b>training solutions</b>, aimed at\n            educating your staff, improving sustainability practices and\n            productivity, as well as optimizing your operational efficiency.\n            <br />\n            Each course is delivered by senior practitioners and structured to\n            provide a tangible return on investment.\n            <br />\n            Tailored to your specific needs and designed for all skill levels,\n            training can take several forms, including, among others, short\n            courses, long-term structured programmes, group sessions and\n            inpidual coaching.\n          </p>\n    <h3>Pharmacovigilance Auditing</h3>\n          <p>\n            Medwork’s auditing process is similar to the approach taken by the\n            EU Competent Authorities. We offer a very well-structured,\n            low-budget pharmacovigilance audit programme in compliance with EU\n            legislation. We perform pharmacovigilance system audits of main\n            functions, affiliates and contractual partners.\n            <br />\n            <br />\n            We can <b>support</b> and <b>coach</b> Marketing Authorization\n            Holders before and after regulatory inspections. We perform mock\n            inspections to ensure adequacy and compliance of pharmacovigilance\n            systems.\n          </p>\n</p>","frontmatter":{"title":"Pharmacovigilance","date":"February 01, 2022","description":"","thumbnail":{"childImageSharp":{"fluid":{"base64":"data:image/jpeg;base64,/9j/2wBDABALDA4MChAODQ4SERATGCgaGBYWGDEjJR0oOjM9PDkzODdASFxOQERXRTc4UG1RV19iZ2hnPk1xeXBkeFxlZ2P/2wBDARESEhgVGC8aGi9jQjhCY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2P/wgARCAAJABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAIDBAX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAQP/2gAMAwEAAhADEAAAAdJGnFpDGS//xAAaEAADAAMBAAAAAAAAAAAAAAAAAQIDERJC/9oACAEBAAEFAuqV1jbJlag8n//EABYRAQEBAAAAAAAAAAAAAAAAABEBEP/aAAgBAwEBPwFZn//EABYRAQEBAAAAAAAAAAAAAAAAAAABEv/aAAgBAgEBPwGNv//EAB0QAAIBBAMAAAAAAAAAAAAAAAABEQIQEnEhMVH/2gAIAQEABj8Cjun0yUScuND0K3//xAAcEAACAgIDAAAAAAAAAAAAAAAAAREhMUFRYbH/2gAIAQEAAT8hTJoydRG4Url0bh8IZl5iP//aAAwDAQACAAMAAAAQrN//xAAYEQACAwAAAAAAAAAAAAAAAAAAEQEhQf/aAAgBAwEBPxCLInp//8QAFhEBAQEAAAAAAAAAAAAAAAAAAREA/9oACAECAQE/EBY5hkN//8QAIBABAAIBAgcAAAAAAAAAAAAAAQARITFBYXGBobHR8P/aAAgBAQABPxCyJ2A9AzIcCFWJnHuXrdN6YxOweYfPgTdzn//Z","aspectRatio":2.236842105263158,"src":"/static/c85d977e29d22fc52a9c5a46e790dbe2/ac53a/pharmacovigilance.jpg","srcSet":"/static/c85d977e29d22fc52a9c5a46e790dbe2/722c4/pharmacovigilance.jpg 340w,\n/static/c85d977e29d22fc52a9c5a46e790dbe2/1d671/pharmacovigilance.jpg 680w,\n/static/c85d977e29d22fc52a9c5a46e790dbe2/ac53a/pharmacovigilance.jpg 1360w,\n/static/c85d977e29d22fc52a9c5a46e790dbe2/eedd9/pharmacovigilance.jpg 1680w","sizes":"(max-width: 1360px) 100vw, 1360px"}}}}}},"pageContext":{"slug":"/pharmacovigilance/","previous":{"fields":{"slug":"/quality-managment/"},"frontmatter":{"title":"Quality Management"}},"next":{"fields":{"slug":"/materiovigilance/"},"frontmatter":{"title":"Materiovigilance"}}}},"staticQueryHashes":["63159454"]}